NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer

NCT00500292

CompletedPhase 2

Sponsor: Genzyme, a Sanofi Company

Conditions: Colorectal, Cancer

Interventions: Vandetanib, FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid

Countries: France, Hungary, Slovakia, South Korea, Spain, Taiwan

The purpose of this study is to determine whether treatment with ZACTIMA (vandetanib) in combination with FOLFOX is more effective than FOLFOX alone for colorectal cancer in patients who have failed therapy with an irinotecan and fluoropyrimidine containing regimen.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Progression on or following treatment for metastatic colorectal cancer
* Have failed therapy with an irinotecan and fluoropyrimidine containing regimen
* Have World Health Organisation (WHO) performance status 0-2 and life expectancy \>12 weeks

Exclusion Criteria:

* Previous treatment with small molecule tyrosine kinase inhibitors of VEGFR or EGFR Prior monoclonal antibodies are permitted, (eg, cetuximab, bevacizumab)
* Previous adjuvant therapy with irinotecan within 12 months of randomisation
* More than one prior course of chemotherapy for treatment of metastatic colorectal cancer

Locations (15)

Lille, France
Toulouse, France
Budapest, Hungary
Debrecen, Hungary
Szeged, Hungary
Bratislava, Slovakia
Poprad, Slovakia
Trnava, Slovakia
Žilina, Slovakia
Seoul, South Korea
Hospitalet deLlobregat, Spain
Oviedo, Spain
Santander, Spain
Taipei, Taiwan
Taoyuan, Taiwan